Three studies on prostate cancer indicate, respectively, that a hypofractionated schedule of intensity-modulated radiation therapy reduces treatment time without negatively affecting quality of life; treatment with stereotactic body radiotherapy is a powerful, potentially more cost-effective option; and prostate brachytherapy, without external radiation, may be sufficient to control disease progression. The data were presented at the American Society for Radiation Oncology's 2016 annual meeting.
Cancer discovery. 2016 Oct 07 [Epub]